No abstract

Homeodomain-interacting protein kinase 2 (HIPK2) is a Ser/Thr kinase controlling cell proliferation and survival, whose investigation has been hampered by the lack of specific inhibitors able to dissect its cellular functions. SB203580, a p38 MAP kinase inhibitor, has been used as a tool to inhibit HIPK2 in cells, but here we show that its efficacy as HIPK2 inhibitor is negligible (IC50>40 µM). In contrast by altering the scaffold of the promiscuous CK2 inhibitor TBI a new class of HIPK2 inhibitors has been generated. One of these, TBID, displays toward HIPK2 unprecedented efficacy (IC50 = 0.33 µM) and selectivity (Gini coefficient 0.592 out of a panel of 76 kinases). The two other members of the HIPK family, HIPK1 and HIPK3, are also inhibited by TBID albeit less efficiently than HIPK2. The mode of action of TBID is competitive with respect to ATP, consistent with modelling. We also provide evidence that TBID is cell permeable by showing that HIPK2 activity is reduced in cells treated with TBID, although with an IC50 two orders of magnitude higher (about 50 µM) than in vitro.

Lines. -Hitherto unknown title compounds of the general structure (III) are obtained by reaction of benzimidazole-substituted enaminones (I) with suitable arylguanidinium nitrates (II). For comparison purposes, the related pyridopyrimidine dione (V) is also synthesized. Compounds (III) inhibit at least four cancer-related protein kinases. The most potent inhibitor (IIIe) inhibits several cancer cell lines of the NCI panel in the submicromolar range. -(DETERMANN, R.; DREHER, J.; BAUMANN, K.; PREU, L.; JONES, P. G.; TOTZKE, F.; SCHAECHTELE, C.; KUBBUTAT, M. H. G.; KUNICK*, C.; Eur. J. Med. Chem. 53 (2012) 254-263, http://dx.

No abstract